Purchase this article with an account.
J.E. Lee, E.C. Mavrofrides, W.E. Smiddy, I.U. Scott, P.J. Rosenfeld, H.W. Flynn Jr, T.G. Murray, A.M. Berrocal, C.A. Puliafito; Intravitreal triamcinolone for the treatment of macular edema from central retinal vein occlusion . Invest. Ophthalmol. Vis. Sci. 2004;45(13):5238.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Objective: To investigate the safety and efficacy of intravitreal triamcinolone for the treatment of vision loss secondary to macular edema from central retinal vein occlusion (CRVO). Methods: Retrospective consecutive case series. The current study included all patients at the Bascom Palmer Eye Institute treated with intravitreal injections of triamcinolone acetonide (4 mg) for the treatment of macular edema from CRVO between June 1, 2001 and June 1, 2003. Results: Forty–one eyes of 41 patients were reviewed. The median age was 78 years old (range, 42–98) with a median follow–up of 6.5 months (2–19). The duration of macular edema was between 1 to 20 months. Median visual acuity was 20/400 (20/60–CF) at baseline. Following treatment, median visual acuity was 20/300 (20/40–CF) at 1 month, 20/300 (20/30–CF) at 3 months, and 20/400 (20/30–LP) at 6 months. The median change in ETDRS equivalent lines was +1 line at 1 month, +2 lines at 3 months, and +2 lines at 6 months. Visual acuity was improved by at least 3 ETDRS equivalent lines in 12/33 eyes (36%) at 1 month, 9/27 (31%) at 3 months, and 11/23 (48%) at 6 months. Median foveal thickness as measured by optical coherence tomography (OCT) was 539 µm (192–768) at baseline, compared to 252 µm (202–632) at 1 month, 313 µm (191–540) at 3 months, and 234 µm (194–602) at 6 months. Additional injections were performed in 2/41 eyes (5%) at 1 month, 7/40 (18%) at 3 months, and 14/27 (52%) at 6 months. Intraocular pressure increased more than 10 mmHg compared to baseline in 5/33 eyes (15%) at 1 month, 4/27 (15%) at 3 months, and 2/23 (9%) at 6 months. There were no cases of endophthalmitis. Rubeosis developed in 8 eyes (20%), and glaucoma filtering surgery was performed in 1 eye (3%). Two patients (5%) experienced significant progression of cataract requiring extraction. Conclusions: In the current study, a 3–line visual acuity improvement occurred in 48% of patients at the 6 month examination, but the median visual acuity was unchanged. Recurrent macular edema and the need for retreatment were common.
This PDF is available to Subscribers Only